Health Boards
ESK-001 is an investigational next-generation tyrosine kinase 2 (TYK2) inhibitor that is designed to correct immune dysregulation across a spectrum of diseases driven by proinflammatory mediators, including IL-23, IL-17, and type 1 interferon (IFN).
ESK-001's selective targeting is designed to deliver maximal inhibition while minimizing off-target binding and effects.
ESK-001 is currently being investigated for the oral treatment of plaque psoriasis and systemic lupus erythematosus (SLE). Potential future indications include psoriatic arthritis, inflammatory bowel disease, and other chronic inflammatory conditions.
Source: alumis.com
ESK-001's selective targeting is designed to deliver maximal inhibition while minimizing off-target binding and effects.
ESK-001 is currently being investigated for the oral treatment of plaque psoriasis and systemic lupus erythematosus (SLE). Potential future indications include psoriatic arthritis, inflammatory bowel disease, and other chronic inflammatory conditions.
Quote:
Safety summary:
ESK-001 (40 mg BID) remained generally safe and well-tolerated over 52 weeks; majority of
TEAEs were mild-to-moderate in severity and self-limited; no safety signals to date
Efficacy summary:
40 mg BID patients showed high levels of response throughout the study
PASI-75 (77.5%), PASI-90 (61.3%) and PASI-100 (38.8%) (mNRI) scores at Week 52
80% of ≥PASI-75 responders at Week 12 in STRIDE maintained or improved their response at Week 52; 62% improved response over 52 weeks of treatment
Rapid and sustained improvement in DLQI 0/1 and itch
ESK-001 pivotal program status:
Onward Phase 3 development program in plaque psoriasis ongoing, with over 600 patients enrolled to date.
Source: alumis.com